SCORAD — SCORing Atopic Dermatitis
European Task Force on Atopic Dermatitis severity index. Total = A/5 + 7B/2 + C, where A = extent (0–100% TBSA), B = sum of 6 intensity items (each 0–3, max 18), C = subjective pruritus + sleep loss VAS (0–20). Pick severity band below — or compute the formula manually.
Score interpretation
→ Emollients ≥4×/day. Mild topical corticosteroid (e.g. hydrocortisone 1%) for flares. Trigger avoidance, education.
→ Potent topical corticosteroid (e.g. betamethasone 0.1%) short courses + emollients. Tacrolimus/pimecrolimus for face/folds. Consider phototherapy referral. Treat infection (S. aureus / HSV).
→ Specialist dermatology referral. Systemic immunosuppression (ciclosporin, methotrexate, dupilumab, baricitinib per NICE TAs). Wet wraps, hospitalisation if widespread infection (e.g. eczema herpeticum).
Interpretation bands for the SCORAD. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Baricitinib 2–4mg (Atopic Dermatitis / Alopecia Areata) · JAK inhibitor (JAK1/JAK2) — systemic immunosuppressant
- Tralokinumab · IL-13 Inhibitor — Atopic Eczema
- Abrocitinib · JAK1 Inhibitor — Atopic Eczema
- Lebrikizumab · IL-13 Inhibitor — Atopic Eczema
- Ciclosporin · Systemic Immunosuppressant — Eczema / Psoriasis
- Azathioprine · Systemic Immunosuppressant — Eczema / Autoimmune Dermatoses
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.